CYBIN
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
CYBIN
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2019-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.cybin.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
124.28 M CAD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-12-14 | Adelia Therapeutics | Adelia Therapeutics acquired by Cybin | 20.16 M CAD |
Investors List
Bail Capital
Bail Capital investment in Series B - Cybin
Life Sciences Partners
Life Sciences Partners investment in Series B - Cybin
RA Capital Management
RA Capital Management investment in Series B - Cybin
Subversive Capital
Subversive Capital investment in Series B - Cybin
Noetic Fund
Noetic Fund investment in Series B - Cybin
Kearny Venture Partners
Kearny Venture Partners investment in Series B - Cybin
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Cybin
Innovating Capital
Innovating Capital investment in Seed Round - Cybin
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-01 | Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development |
Official Site Inspections
http://www.cybin.com Semrush global rank: 1.98 M Semrush visits lastest month: 10.8 K
- Host name: 77.141.27.34.bc.googleusercontent.com
- IP address: 34.27.141.77
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cybin"
CYB004 - Cybin
Cybin’s portfolio includes the most advanced and extensive DMT and deuterated DMT (“dDMT”) dataset in the neuropsychiatry drug development sector. Cybin’s internal research has also …See details»
EMBARK - Cybin
Cybin will use EMBARK as a psychological support model for all of its clinical trials and is partnering with other leading institutions to adopt tailored treatment approaches. EMBARK’s six-domain structure was designed to be a modular, …See details»
Cybin - Crunchbase Company Profile & Funding
Cybin may be growing as it is reported to raise $150 million through a private placement, which indicates a significant influx of capital that can be used for …See details»
Cybin - Investor Relations
4 days ago Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people …See details»
Cybin Corporation - Psychedelic Science Review
Cybin Corporation. Cybin Corp is a Canadian biotechnology company founded in 2019. Originally embracing both pharmaceutical and nutraceutical fungi-based products, Cybin is now solely …See details»
Cybin - Contacts, Employees, Board Members, Advisors & Alumni
Cybin has 16 current employee profiles, including Co-Founder, Executive Chairman and President Eric So. Eric So Co-Founder, Executive Chairman and President John Kanakis Co-Founder …See details»
Cybin - Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 ...
Nov 13, 2024 Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, …See details»
Cybin - Funding, Financials, Valuation & Investors - Crunchbase
Cybin is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... Which …See details»
Our Team - Cybin
Prior to his current role at Cybin, Dr. Kelman was the Director of Training of the UCLA Prevention Center of Excellence in the Semel Institute for Neuroscience and Human Behavior. Dr. Kelman has published manuscripts on behavioral …See details»
Cybin Inc - LinkedIn
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression - Cybin (AMEX:CYBN) benzinga.comSee details»
Cybin Inc. (CYBN.NE) Stock Price, News, Quote & History - Yahoo …
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline …See details»
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for …
TORONTO, March 14, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing …See details»
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 …
Nov 13, 2024 This news release constitutes a "designated news release" for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf …See details»
Cybin - Investors
At Cybin, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting …See details»
Partnerships - Cybin
Cybin has partnered with Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, to …See details»
Facet Life Sciences Named Regulatory Partner for Cybin's ...
3 days ago About Cybin Cybin is a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next …See details»
Cybin Inc. Reports First Quarter Financial Results and Recent …
Aug 8, 2022 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticSee details»
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating ...
Nov 18, 2024 TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry …See details»
CYB003 - Cybin
CYB003 is a proprietary deuterated psilocin molecule. Psilocin is part of a family of molecules called indoleamines that are structurally similar to neurotransmitters such as serotonin, and …See details»
Cybin to Participate in Water Tower Research Fireside Chat on …
3 days ago Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment …See details»